Demographic and disease factors at baseline
| Placebo+MTX (n=63)* | TCZ+MTX (n=69) | |
|---|---|---|
| Female, n (%) | 47 (75) | 57 (83) |
| Age, years | 57.0 (50.0–64.0) | 57.0 (49.0–62.0) |
| Weight, kg | 82.0 (65.0–92.1) | 77.4 (67.0–86.5) |
| BMI, kg/m2, median (range) | 29.2 (18.5–49.6) | 29.2 (19.4–57.3) |
| Current smoker, n (%) | 14 (22) | 19 (28) |
| History of diabetes, n (%) | 4 (6) | 6 (9) |
| Duration of RA, years | 6.8 (2.4–9.9) | 7.0 (2.0–16.2) |
| DAS28 | 6.6 (5.8–7.3) | 6.8 (5.9–7.4) |
| CRP, mg/dL | 0.88 (0.39–1.86) | 0.94 (0.52–2.65) |
| Statin use, n (%) | 10 (16) | 10 (14) |
| Previous aTNF, n (%) | 19 (30) | 27 (39) |
| Oral steroid use, n (%) | 17 (27) | 20 (29) |
| Baseline MTX dose, mg/week | 15.0 (15.0–20.0) | 15.0 (15.0–20.0) |
Data are presented as median (IQR) unless otherwise indicated.
*One patient randomly assigned to placebo+MTX actually received one dose of TCZ and was therefore included in the TCZ group for the safety analyses.
aTNF, anti-tumour necrosis factor α; BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score at 28 joints; MTX, methotrexate; RA, rheumatoid arthritis; TCZ, tocilizumab.